Latest News and Press Releases

First subject dosed in pivotal Phase III program evaluating TWIN in subjects with moderate-to-severe acne vulgaris Two Phase III trials expected to enroll a total of approximately 840 subjects ...

NESS ZIONA, Israel, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...

NESS ZIONA, Israel, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...

NESS ZIONA, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...

NESS ZIONA, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...

NESS ZIONA, Israel, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...

Patient enrollment of the pivotal Phase III Epsolay clinical trials is on schedule Top-line results expected in 2019 NESS ZIONA, Israel, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies...

NESS ZIONA, Israel, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...

Announces Positive End-of-Phase II Meeting with the FDA Receives Special Protocol Assessment (SPA) Agreement from FDA Company expects to commence the TWIN Phase III clinical trials in the fourth...

NESS ZIONA, Israel, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...